{"id":9736,"date":"2025-03-07T17:38:18","date_gmt":"2025-03-07T09:38:18","guid":{"rendered":"https:\/\/www.excelsiormedical.com.tw\/?p=9736"},"modified":"2025-03-11T15:19:38","modified_gmt":"2025-03-11T07:19:38","slug":"the-board-of-directors-approved-new-shares-for-capital-increase-by-earnings-recapitalization-3","status":"publish","type":"post","link":"https:\/\/www.excelsiormedical.com.tw\/en\/investors\/the-board-of-directors-approved-new-shares-for-capital-increase-by-earnings-recapitalization-3\/","title":{"rendered":"The Board of Directors approved new shares for capital increase by earnings recapitalization."},"content":{"rendered":"

 <\/p>\n\n\n\n\n\n\n
SEQ_NO<\/td>\n\u00a03<\/td>\nDate of announcement<\/td>\n2025\/03\/07<\/td>\nTime of announcement<\/td>\n17:36:59<\/td>\n<\/tr>\n
Subject<\/td>\n\n
The Board of Directors approved new shares for capital increase by earnings recapitalization.<\/pre>\n<\/td>\n<\/tr>\n
Date of events<\/td>\n2025\/03\/07<\/td>\nTo which item it meets<\/td>\nparagraph 11<\/td>\n<\/tr>\n
Statement<\/td>\n\n
1.Date of the board of directors resolution:2025\/03\/07\r\n2.Source of capital increase funds:\r\n  Earnings recapitalization.\r\n3.Whether to adopt shelf registration (Yes, please state\r\n  issuance period\/No):No.\r\n4.Total monetary value of the issuance and number of shares\r\n  issued (shares issued not including those distributed to \r\n  employees if consisting in capital increase from earnings\r\n  or capital surplus):NT$ 81,698,790 and 8,169,879 shares.\r\n5.If adopting shelf registration, monetary value and number\r\n  of shares to be issued this time:Not Applicable.\r\n6.The remaining monetary value and shares after this \r\n  issuance when adopting shelf registration:Not Applicable.\r\n7.Par value per share:NT$10.\r\n8.Issue price:Not Applicable.\r\n9.Number of shares subscribed for by or allocated to\r\n  employees:Not Applicable.\r\n10.Number of shares publicly sold:Not Applicable.\r\n11.Ratio of shares subscribed by or allotted as stock \r\n   dividends to existing shareholders:50 shares \r\n   gratuitously allotted for every thousand shares.\r\n12.Handling method for fractional shares and shares \r\n   unsubscripted for by the deadline:\r\n   If the new shares distributed to shareholders from this \r\n   capital increase are less than one full share(rounded\r\n   down to the NT dollar), shareholders may consolidate \r\n   them by handling respective procedures. For those shares\r\n   which cannot be consolidated within the specified period\r\n   or still remain insufficient, and the chairman shall be \r\n   authorized to designate specific persons for purchase of\r\n   these.\r\n13.Rights and obligations of these newly issued shares:\r\n   The same as the original shares.\r\n14.Utilization of the funds from the capital increase:\r\n   To enhance financial and capital structure.\r\n15.Any other matters that need to be specified:\r\n   If the number of shares outstanding is affected and \r\n   shareholding ratio is thus affected, the chairman will \r\n   be fully authorized for handling such matter.\r\n<\/pre>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"
  SEQ_NO \u00a03 Date of announcement 2025\/03\/07 Time of announcement 17:36:59 Subject The Board of Directors approved new shares for capital increase by earnings recapitalization. Date of events 2025\/03\/07 To which item it meets paragraph 11 Statement 1.Date of the board of directors resolution:2025\/03\/07 2.Source of capital increase funds: Earnings recapitalization. 3.Whether to adopt shelf …<\/p>\n
  The Board of Directors approved new shares for capital increase by earnings recapitalization.<\/span> Read More »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[72,102],"tags":[],"class_list":["post-9736","post","type-post","status-publish","format-standard","hentry","category-investors","category-material-information"],"_links":{"self":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/comments?post=9736"}],"version-history":[{"count":2,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9736\/revisions"}],"predecessor-version":[{"id":9739,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9736\/revisions\/9739"}],"wp:attachment":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/media?parent=9736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/categories?post=9736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/tags?post=9736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}